Hypoglycemic Agents

"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances which lower blood glucose levels.

Descriptor ID	D007004
MeSH Number(s)	D27.505.696.422
Concept/Terms	Hypoglycemic Agents Hypoglycemic Agents Agents, Hypoglycemic Antihyperglycemics Antihyperglycemic Agents Agents, Antihyperglycemic Hypoglycemic Drugs Drugs, Hypoglycemic Hypoglycemics Hypoglycemic Effect Hypoglycemic Effect Effect, Hypoglycemic Hypoglycemic Effects Effects, Hypoglycemic Antidiabetics Antidiabetics Antidiabetic Drugs Drugs, Antidiabetic Antidiabetic Agents Agents, Antidiabetic

Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hypoglycemic Agents [D27.505.696.422]

Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.

Bar chart showing 179 publications over 25 distinct years, with a maximum of 13 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2002	4	2	6
2003	2	3	5
2004	1	4	5
2005	9	2	11
2006	4	1	5
2007	1	5	6
2008	3	7	10
2009	6	2	8
2010	3	4	7
2011	8	1	9
2012	4	4	8
2013	7	4	11
2014	7	2	9
2015	7	6	13
2016	8	1	9
2017	8	4	12
2018	2	2	4
2019	8	1	9
2020	4	3	7
2021	1	6	7
2022	0	3	3
2023	0	3	3
2024	2	3	5
2025	5	1	6

Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.

Bramante CT, Stewart TG, Boulware DR, McCarthy MW, Gao Y, Rothman RL, Mourad A, Thicklin F, Cohen JB, Garcia Del Sol IT, Ruiz-Unger J, Shah NS, Mehta M, Cardona OQ, Scott J, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, Collins S, Dunsmore SE, Adam SJ, Lindsell CJ, Hernandez AF, Naggie S. Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 01; 185(9):1092-1101.

View in: PubMed
Ramsey DJ, Makwana B, Dani SS, Patel M, Panchal K, Shah J, Khadke S, Kumar A, Patel T, Kosiborod MN, Fonarow GC, Ramsey KM, Nohria A, Butler J, Ganatra S. GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes. JAMA Netw Open. 2025 Aug 01; 8(8):e2526321.

View in: PubMed
Liu F, Zhao B, Wang Q, Lei Z, McClements DJ, Wang S, Chen S. Potential application of quercetin as an anti-diabetic treatment: From molecular mechanism to delivery system design. Phytomedicine. 2025 Sep; 145:157036.

View in: PubMed
Collier JJ, Wasserfall CH, Brehm MA, Karlstad MD. Partial remission of type 1 diabetes: Do immunometabolic events define the honeymoon period? Diabetes Obes Metab. 2025 Aug; 27(8):4092-4101.

View in: PubMed
Arian CM, O'Mahony ET, Manwill PK, Graf TN, Oberlies NH, Cech NB, Clarke JD, Smith JG, Paine MF, Kelly EJ, Thummel KE. A gut response: Application of human enteroid monolayers to probe the mechanism of the goldenseal-mediated inhibition of metformin intestinal absorption. J Pharmacol Exp Ther. 2025 Jun; 392(6):103597.

View in: PubMed
Wilkie G, Payne A, Baltich Nelson B, Whelan AR. Early gestational diabetes mellitus and the effect of metformin use on perinatal outcomes: a systematic review. Minerva Obstet Gynecol. 2025 Jun; 77(3):215-218.

View in: PubMed
Sawalha K, Gautam N, Sivakumar K, Paydak H, Mehta JL. Metformin: Its salutary effects beyond diabetes mellitus. J Investig Med. 2025 Jun; 73(5):363-375.

View in: PubMed
Bisht P, Bhattacharya A, Pal A, Singh R, Verma SK. Design and synthesis of novel 3,7-dihydro-1H-purine-2,6-diones as DPP-4 inhibitors: An in silico, in vitro and in vivo approach. Eur J Med Chem. 2025 Feb 05; 283:117160.

View in: PubMed
Khadke S, Kumar A, Bhatti A, Dani SS, Al-Kindi S, Nasir K, Virani SS, Upadhyay J, Garcia-Banigan DC, Abraham S, Husami R, Kong Y, Labib S, Venesy D, Shah S, Lenihan D, Vaduganathan M, Deswal A, Fonarow GC, Butler J, Nohria A, Kosiborod MN, Ganatra S. GLP-1 Receptor Agonist in Nonobese Patients with Type 2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction. J Card Fail. 2025 Jul; 31(7):989-1001.

View in: PubMed
Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, Banker A, Husami Z, Labib S, Venesy D, Fonarow G, Kosiborod M, Al-Kindi S, Bhatt DL, Dani S, Nohria A, Butler J, Ganatra S. GLP-1 Receptor Agonists Among Patients?With Overweight or Obesity,?Diabetes,?and HFpEF on SGLT2?Inhibitors. JACC Heart Fail. 2024 Nov; 12(11):1814-1826.

View in: PubMed

People

Explore

Similar Concepts

Top Journals